A detailed history of Hood River Capital Management LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Hood River Capital Management LLC holds 8,144,637 shares of IOVA stock, worth $66.3 Million. This represents 1.42% of its overall portfolio holdings.

Number of Shares
8,144,637
Previous 2,732,427 198.07%
Holding current value
$66.3 Million
Previous $21.9 Million 248.99%
% of portfolio
1.42%
Previous 0.54%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.28 - $11.9 $39.4 Million - $64.4 Million
5,412,210 Added 198.07%
8,144,637 $76.5 Million
Q2 2024

Aug 14, 2024

BUY
$7.78 - $14.19 $841,710 - $1.54 Million
108,189 Added 4.12%
2,732,427 $21.9 Million
Q1 2024

May 15, 2024

BUY
$7.59 - $17.47 $4.73 Million - $10.9 Million
622,728 Added 31.11%
2,624,238 $38.9 Million
Q4 2023

Feb 14, 2024

BUY
$3.3 - $8.89 $30,277 - $81,565
9,175 Added 0.46%
2,001,510 $16.3 Million
Q3 2023

Nov 14, 2023

BUY
$4.44 - $8.79 $74,520 - $147,531
16,784 Added 0.85%
1,992,335 $9.07 Million
Q2 2023

Aug 14, 2023

BUY
$5.36 - $9.06 $10.6 Million - $17.9 Million
1,975,551 New
1,975,551 $13.9 Million
Q2 2021

Aug 13, 2021

SELL
$16.33 - $33.07 $7.52 Million - $15.2 Million
-460,679 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$28.67 - $52.59 $1.28 Million - $2.35 Million
-44,732 Reduced 8.85%
460,679 $14.6 Million
Q4 2020

Feb 16, 2021

BUY
$28.04 - $50.26 $239,629 - $429,521
8,546 Added 1.72%
505,411 $23.5 Million
Q3 2020

Nov 16, 2020

SELL
$27.75 - $36.3 $1.4 Million - $1.83 Million
-50,447 Reduced 9.22%
496,865 $16.4 Million
Q2 2020

Aug 14, 2020

BUY
$27.21 - $41.0 $14.9 Million - $22.4 Million
547,312 New
547,312 $15 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.28B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Hood River Capital Management LLC Portfolio

Follow Hood River Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hood River Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hood River Capital Management LLC with notifications on news.